FDA PMTA Decisions Q3 2026: Latest Authorizations and Market Impact

TL;DR

The FDA issued one new nicotine pouch authorization in Q3 2026: on! PLUS Mint 3mg, expanding Helix Innovations' (Altria) authorized portfolio to 7 SKUs. This marks the 27th total nicotine pouch marketing authorization since the agency began clearing products in January 2025. Major brands including VELO, Rogue, Lucy, and FRE continue operating with PMTAs pending review as the FDA maintains its cautious approach to oral nicotine products.

The Latest Authorization: on! PLUS Mint 3mg

On July 18, 2026, the FDA authorized on! PLUS Mint 3mg, the first 3mg variant to receive marketing authorization in the on! PLUS line. Previously, Helix Innovations received authorization for six products in December 2025—all in 6mg and 9mg strengths across Mint, Tobacco, and Wintergreen flavors.

The new authorization brings the on! PLUS portfolio to:

According to the FDA's press announcement, the agency determined this product met the "appropriate for the protection of public health" standard required under the Family Smoking Prevention and Tobacco Control Act.

Current Landscape: Only Two Brands Authorized

As of August 2026, only two nicotine pouch brands hold FDA marketing authorization:

ZYN (Swedish Match/Philip Morris International): 20 SKUs authorized January 16, 2025. All products contain 15 pouches per can and are available in 3mg and 6mg strengths across 10 flavors. ZYN remains the market leader in the authorized category.

on! PLUS (Helix Innovations/Altria): 7 SKUs now authorized following the Q3 2026 Mint 3mg decision. All products contain 20 pouches per can.

This creates a significant regulatory divide in the marketplace. Major competitors continue operating under the enforcement discretion policy outlined in the FDA's premarket tobacco product application guidance.

What This Means for Consumers 21 and Older

For adult nicotine pouch users 21 and older, the Q3 2026 decision expands lower-strength options in the authorized category. The on! PLUS Mint 3mg authorization provides the first FDA-authorized entry-level product outside the ZYN portfolio.

Key consumer considerations:

• Limited authorized choices: Only 27 total SKUs have received FDA marketing authorization, while dozens of non-authorized products remain available with PMTAs pending review
• No cessation claims: FDA authorization does not mean these products are approved for smoking cessation or therapeutic use
• Strength options: Authorized products now range from 3mg to 9mg nicotine per pouch
• Can sizes vary: ZYN authorized products contain 15 pouches, while on! PLUS contains 20

Consumers should understand that "FDA authorized" is distinct from "FDA approved." The authorization means the FDA determined marketing these specific products is appropriate for public health—not that the products are safe or recommended. The FDA's tobacco products overview clearly states there is no safe tobacco product.

Industry Impact and Pending Applications

The slow pace of authorizations continues to create market uncertainty. Brands operating without authorization face potential marketing denial orders at any time.

Brands with PMTAs pending review (not authorized as of August 2026):

• VELO (R.J. Reynolds/BAT): Has submitted a PMTA but has not received FDA marketing authorization. Products contain 20 pouches per can.
• Rogue (Swisher International): PMTA submitted, not authorized as of August 2026. Products contain 20 pouches per can.
• Lucy (Lucy Goods Inc.): PMTA under FDA review. Products contain 15 pouches per can.
• FRE (Turning Point Brands): Has submitted a PMTA but lacks FDA marketing authorization as of August 2026. Products contain 20 pouches per can.

These brands submitted applications by the September 9, 2020 deadline and remain on the market while the FDA conducts reviews. However, the agency's timeline remains unpredictable—some applications have been under review for nearly six years.

What's Next: Fall 2026 and Beyond

Industry observers expect additional PMTA decisions before year-end, though the FDA has not published a review schedule. Potential developments include:

1. Additional flavor authorizations: The FDA may authorize additional on! PLUS flavors or strengths from Helix's submitted portfolio
2. First decisions on major brands: VELO, Rogue, or other high-volume brands could receive first authorizations or denials
3. Mint/menthol policy clarification: The FDA continues reviewing flavored products under its stated public health framework outlined in the Tobacco Control Act
4. Marketing denial orders: The FDA could issue denials for products determined not appropriate for public health protection

The agency continues operating under Acting Commissioner authority following leadership transitions, which may influence review timelines. Stakeholders can monitor updates through the FDA's tobacco product center.

Regulatory Outlook

The Q3 2026 authorization demonstrates the FDA's continued willingness to authorize oral nicotine products meeting its public health standard. However, the limited number of authorizations—just 27 SKUs across two brands—shows the agency remains highly selective.

For the broader nicotine pouch industry, the regulatory landscape remains in flux. Authorized brands gain competitive advantages through retail placement and consumer confidence, while non-authorized competitors face ongoing uncertainty despite years of market presence.

Adult consumers 21 and older should expect continued market evolution as the FDA works through the PMTA backlog and issues additional decisions in the coming months.